(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback